Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Published
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Full ArticlePublished
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Full ArticleAfter a dismal performance so far in 2024, a $300 price target might seem like a stretch. Is the stock finally a buy?
One analyst expects Disney's free cash flow to soar.